TP53 Clinical Trials in Beijing, Beijing Municipality

2 recruitingBeijing, Beijing Municipality, China

Filters

Status

RecruitingNot yet recruitingEnrolling by invitationActive, not recruiting

Sex

MaleFemale

Your Age

Shows trials you qualify for by age

Phase

Phase 1Phase 2Phase 3Phase 4Early Phase 1Not Applicable

Study Type

InterventionalObservational

Country

United StatesCanadaUnited KingdomAustraliaGermanyFranceSpainItaly

Other Locations

Minneapolis, Minnesota2
Nanjing, Jiangsu1
Boston, Massachusetts1
Foxborough, Massachusetts1
Milford, Massachusetts1
Weymouth, Massachusetts1
Xiamen, Fujian1

Showing 1–2 of 2 trials

Recruiting

Phase 2

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial CarcinomaTP53 MutationRecurrent or Metastatic

Cancer Institute and Hospital, Chinese Academy of Medical Sciences117 enrolled1 locationNCT06413992

Recruiting

Phase 1

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Solid Tumor, AdultLymphomaEphA2 Overexpression+4 more

Chinese PLA General Hospital10 enrolled1 locationNCT05631886

ClinicalTrialsFinder

Helping patients and researchers find recruiting clinical trials. Updated regularly from ClinicalTrials.gov and ANZCTR.

Browse

Browse Conditions
Browse Drugs
Browse Locations
Browse Institutions
Search Trials
Get Trial Alerts

Resources

Clinical Trial Guides
FAQ
About Us
Contact
ClinicalTrials.gov
ANZCTR

Data Source

Trial data sourced from ClinicalTrials.gov and ANZCTR (Australian New Zealand Clinical Trials Registry)

Updated regularly to reflect the latest trial information

Medical Disclaimer: This site is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making decisions about participating in a clinical trial. Trial information may change; verify details directly with the trial sponsor or at the relevant registry (ClinicalTrials.gov or ANZCTR).

|

Privacy Policy Terms of Service

Data provided by ClinicalTrials.gov & ANZCTR